What you need to know about cellphones, rats and cancer: Putting it into perspective Nearly 92 percent of all Americans own cellphones, and for the last 20 years there has been much debate as to the long-term health effects of their use.
Skin cancer checks at primary care doctors' visits could save lives, study suggests As rates of melanoma rise, scientists at the University of Pittsburgh School of Medicine are suggesting a possible solution: screenings at primary care physicians’ (PCP) offices.
Study puts another feather in Mediterranean diet's cap Women who've survived breast cancer and are looking to prevent a recurrence may be encouraged by news out of a major cancer conference: that adhering to a Mediterranean diet (lots of fruits, veggies, fish, and olive oil) may help fend off the disease's return, the Guardian reports.
New studies rely on the Internet for help treating cancer patients New reports on two web-based cancer initiatives provide fresh evidence for the potential of the internet to give patients more influence over the research and treatment of their diseases.
Biden unveiling public database for clinical data on cancer WASHINGTON (AP) -- Vice President Joe Biden unveiled a public database for clinical data on cancer on Monday that aims to help researchers and doctors better tailor new treatments to individuals.
Mother of 3 takes on dead friend's 6 children When Beth Laitkep's breast cancer spread to her brain and spine, doctors knew she didn't have much time.
Novartis study shows skin cancer combo also works on lungs A Novartis trial of two drugs against an aggressive lung cancer bodes well for broadening their use beyond melanoma, the Swiss drugmaker told the American Society of Clinical Oncology's conference in Chicago on Tuesday.
Study finds cancer drug prices highest in U.S.; least affordable in India, China Americans pay the highest prices in the world for cancer drugs, but the treatments are least affordable in lower income countries, according to the results of a new study released on Monday.
AstraZeneca cuts costs and doubles down on cancer drugs AstraZeneca is to cut costs by $1 billion and increase its focus on cancer treatments after underlying earnings, hit by drug patent expiries, fell 12 percent in the first quarter, broadly in line with analyst expectations.
